Postpartum hemorrhage in the developed world: Whither misoprostol?

Karen Gibbins, Catherine M. Albright, Dwight J. Rouse

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

We reviewed the literature to determine the optimal medical treatment of postpartum hemorrhage caused by uterine atony. Of the available uterotonics, only misoprostol and oxytocin have undergone rigorous comparative study. Of the 2, misoprostol is inferior: 2 recent well-done randomized trials with enrollment of more than 2200 patients demonstrated that, in situations in which prophylactic oxytocin has already been utilized, additional oxytocin is as effective as or better than misoprostol in terminating bleeding, while avoiding the high rate of fever (22-58%) associated with misoprostol. The second of these trials demonstrated that misoprostol does not augment the effect of oxytocin. We conclude that in settings in which oxytocin is available, oxytocin should remain the mainstay of both prophylaxis and first-line treatment of postpartum hemorrhage caused by uterine atony. In the developed world, the use of misoprostol for postpartum hemorrhage should be infrequent.

Original languageEnglish (US)
Pages (from-to)181-183
Number of pages3
JournalAmerican journal of obstetrics and gynecology
Volume208
Issue number3
DOIs
StatePublished - Mar 1 2013
Externally publishedYes

Fingerprint

Postpartum Hemorrhage
Misoprostol
Oxytocin
Uterine Inertia
Fever
Hemorrhage
Therapeutics

Keywords

  • misoprostol
  • oxytocin prophylaxis
  • postpartum hemorrhage

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Postpartum hemorrhage in the developed world : Whither misoprostol? / Gibbins, Karen; Albright, Catherine M.; Rouse, Dwight J.

In: American journal of obstetrics and gynecology, Vol. 208, No. 3, 01.03.2013, p. 181-183.

Research output: Contribution to journalArticle

Gibbins, Karen ; Albright, Catherine M. ; Rouse, Dwight J. / Postpartum hemorrhage in the developed world : Whither misoprostol?. In: American journal of obstetrics and gynecology. 2013 ; Vol. 208, No. 3. pp. 181-183.
@article{45961756e7e44072bed98e8a876cff7a,
title = "Postpartum hemorrhage in the developed world: Whither misoprostol?",
abstract = "We reviewed the literature to determine the optimal medical treatment of postpartum hemorrhage caused by uterine atony. Of the available uterotonics, only misoprostol and oxytocin have undergone rigorous comparative study. Of the 2, misoprostol is inferior: 2 recent well-done randomized trials with enrollment of more than 2200 patients demonstrated that, in situations in which prophylactic oxytocin has already been utilized, additional oxytocin is as effective as or better than misoprostol in terminating bleeding, while avoiding the high rate of fever (22-58{\%}) associated with misoprostol. The second of these trials demonstrated that misoprostol does not augment the effect of oxytocin. We conclude that in settings in which oxytocin is available, oxytocin should remain the mainstay of both prophylaxis and first-line treatment of postpartum hemorrhage caused by uterine atony. In the developed world, the use of misoprostol for postpartum hemorrhage should be infrequent.",
keywords = "misoprostol, oxytocin prophylaxis, postpartum hemorrhage",
author = "Karen Gibbins and Albright, {Catherine M.} and Rouse, {Dwight J.}",
year = "2013",
month = "3",
day = "1",
doi = "10.1016/j.ajog.2012.07.034",
language = "English (US)",
volume = "208",
pages = "181--183",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Postpartum hemorrhage in the developed world

T2 - Whither misoprostol?

AU - Gibbins, Karen

AU - Albright, Catherine M.

AU - Rouse, Dwight J.

PY - 2013/3/1

Y1 - 2013/3/1

N2 - We reviewed the literature to determine the optimal medical treatment of postpartum hemorrhage caused by uterine atony. Of the available uterotonics, only misoprostol and oxytocin have undergone rigorous comparative study. Of the 2, misoprostol is inferior: 2 recent well-done randomized trials with enrollment of more than 2200 patients demonstrated that, in situations in which prophylactic oxytocin has already been utilized, additional oxytocin is as effective as or better than misoprostol in terminating bleeding, while avoiding the high rate of fever (22-58%) associated with misoprostol. The second of these trials demonstrated that misoprostol does not augment the effect of oxytocin. We conclude that in settings in which oxytocin is available, oxytocin should remain the mainstay of both prophylaxis and first-line treatment of postpartum hemorrhage caused by uterine atony. In the developed world, the use of misoprostol for postpartum hemorrhage should be infrequent.

AB - We reviewed the literature to determine the optimal medical treatment of postpartum hemorrhage caused by uterine atony. Of the available uterotonics, only misoprostol and oxytocin have undergone rigorous comparative study. Of the 2, misoprostol is inferior: 2 recent well-done randomized trials with enrollment of more than 2200 patients demonstrated that, in situations in which prophylactic oxytocin has already been utilized, additional oxytocin is as effective as or better than misoprostol in terminating bleeding, while avoiding the high rate of fever (22-58%) associated with misoprostol. The second of these trials demonstrated that misoprostol does not augment the effect of oxytocin. We conclude that in settings in which oxytocin is available, oxytocin should remain the mainstay of both prophylaxis and first-line treatment of postpartum hemorrhage caused by uterine atony. In the developed world, the use of misoprostol for postpartum hemorrhage should be infrequent.

KW - misoprostol

KW - oxytocin prophylaxis

KW - postpartum hemorrhage

UR - http://www.scopus.com/inward/record.url?scp=84874780748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874780748&partnerID=8YFLogxK

U2 - 10.1016/j.ajog.2012.07.034

DO - 10.1016/j.ajog.2012.07.034

M3 - Article

C2 - 22901709

AN - SCOPUS:84874780748

VL - 208

SP - 181

EP - 183

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 3

ER -